Review of tipranavir in the treatment of drug-resistant HIV.

about

The higher barrier of darunavir and tipranavir resistance for HIV-1 protease

P2860

Q27672193-2E08D018-6584-43ED-94C2-12D4013DF69E

P2860

Review of tipranavir in the treatment of drug-resistant HIV.

Item

http://www.wikidata.org/entity/Q36642990

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Review of tipranavir in the treatment of drug-resistant HIV.

@ast

Review of tipranavir in the treatment of drug-resistant HIV.

@en

type

Item

label

Review of tipranavir in the treatment of drug-resistant HIV.

@ast

Review of tipranavir in the treatment of drug-resistant HIV.

@en

prefLabel

Review of tipranavir in the treatment of drug-resistant HIV.

@ast

Review of tipranavir in the treatment of drug-resistant HIV.

@en

P1476

Review of tipranavir in the treatment of drug-resistant HIV

@en

P2093

Jürgen Kurt Rockstroh

http://www.w3.org/2001/XMLSchema#string

P2860

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor.

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

P304

641-651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hendrik Streeck

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18472987

http://www.w3.org/2001/XMLSchema#string

P932

2374948

http://www.w3.org/2001/XMLSchema#string

Review of tipranavir in the treatment of drug-resistant HIV.

about

P2860

P2860

Review of tipranavir in the treatment of drug-resistant HIV.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932